Clinical Trials Directory

Trials / Completed

CompletedNCT00888342

Changes in Blood Gases, Disturbance of Breath During Sleep and Cardiovascular Co-morbidity in COPD Patients

A Study of Changes in Blood Gases, Disturbance of Breath During Sleep and Cardiovascular Co-morbidity in Patients With COPD in Different Stages of the Disease, and the Effect of Alcohol, Supplementary Oxygen and Zopiclone on These Changes.

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
150 (actual)
Sponsor
LHL Helse · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Respiration failure type 2 is loss of the lungs ability to take up oxygen (O2) and get rid of carbon dioxide (CO2). The diagnosis is based on blood gas measurement of pressures of O2 and CO2. Patients with COPD is often seen to have co-morbidity with cardiac diseases. Chronic systemic inflammation is seen in both COPD and cardiac diseases. The investigators will investigate the sleep quality, CO2-retention, O2-saturation, cardiac arrythmias and markers of inflammation in 120 patients with COPD in different stages of the disease. Our hypotheses are: * that the first signs of respiration failure type 2 is seen during sleep with alteration of sleep patterns and greater and more long-lasting retention of CO2 in the blood compared to those with a normal lung function * that the use of alcohol, zopiclone or supplementary oxygen will make these differences even greater * that cardiac arrythmias correlates with hypoxemia * that cardiac arrythmias and respiration failure correlates with degree of inflammation

Conditions

Interventions

TypeNameDescription
DRUGsupplementary oxygenSupplementary oxygen 2 L/min if SpO2 \< 90%. If SpO2 \< 90 % the oxygen dose is titrated until SpO2 reads 88-92%. For patients on LTOT the oxygen dose is doubled for intervention.
DRUGzopiclone5 mg sedative given approximately 1 hour before sleep
OTHERalcohol5 mg alcohol/kg body-weight approximately 1 hour before sleep

Timeline

Start date
2009-05-01
Primary completion
2011-07-01
Completion
2011-07-01
First posted
2009-04-27
Last updated
2012-05-16

Locations

2 sites across 1 country: Norway

Source: ClinicalTrials.gov record NCT00888342. Inclusion in this directory is not an endorsement.